Clinical trial
A Randomized, Open-Label, Phase 2 Study of a Patient-Specific Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer With Minimal Residual Disease Following Surgical Resection and Standard Adjuvant Chemotherapy
NCT05456165 is registered in ClinicalTrials.gov with Gritstone bio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-Label, Phase 2 Study of a Patient-Specific Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer With Minimal Residual Disease Following Surgical Resection and Standard Adjuvant Chemotherapy
- Lead sponsor
- Gritstone bio, Inc.
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- May 19, 2022
- Completion date
- September 1, 2022
- Enrollment
- 0 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.